Results and discussion
To investigate the effect of activated ras on the expression of Bak in intestinal epithelial cells, we first compared the levels of Bak in the parental non-malignant IEC-18 cells and in IEC-ras-3 and IEC-ras-4, two clones of cells that were independently generated by transfection of IEC-18 cells with activated H-ras [9, 10] . In monolayer culture, rastransformed clones expressed significantly lower amounts of Bak than the IEC-18 cells (Figure 1a) . A similar reduction of Bak expression was observed when cells were placed in suspension (data not shown). The ras-induced downregulation of Bak was also observed by northern blot analysis (see Supplementary material published with this paper on the internet). In addition, we also studied the effect of activated ras on Bak expression in a clone obtained by transfecting IEC-18 cells with a vector carrying an activated H-ras gene under the control of a dexamethasone-inducible mouse mammary tumour virus (MMTV) promoter (MMTV-ras) [9] . In agreement with the results obtained with the clones that constitutively expressed activated H-ras, Bak levels were downregulated upon treatment of the MMTV-ras clone with dexamethasone ( Figure 1b ). Similar treatment of parental IEC-18 cells did not affect Bak levels ( Figure 1c ).
To verify that ras-induced downregulation of Bak also occurs in human colorectal cancer cells, we examined Bak Expression of activated H-ras and K-ras in intestinal epithelial cells results in a reduction of levels of Bak. (a) Western blot analysis of Bak in IEC-18 cells and two independently derived H-ras-transformed clones, IEC-ras-3 (ras-3) and IEC-ras-4 (ras-4). (b) IEC-18 cells carrying the H-ras gene under the control of the dexamethasoneinducible MMTV promoter, before (0 h) and after induction with 1 µM dexamethasone (dex) for 24, 36 and 48 h. The same cell lysates were independently assessed for the expression of H-ras. (c) IEC-18 cells before and after treatment with 1 µM dexamethasone for 48 h. In (a-c), the membrane was also incubated with anti-Cdk4 antibody as a loading control. (d) Western blot analysis of the colorectal tumor cell line HCT 116, which carries activated K-ras, and its derivative cell line HKh-2, in which the activated K-ras allele was deleted by targeted disruption. The membrane was incubated with anti-E-cadherin antibody as a loading control. A polyclonal Bak antibody (UBI) generated against a synthetic peptide corresponding to residues 23-37 of human Bak (also present in the mouse homologue) was used in (a-d). 
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Bak E-cadherin H-ras expression in the highly tumorigenic HCT 116 cell line, which carries an activated K-ras gene, and in its derivative cell line Hkh-2, in which the activated K-ras allele has been deleted by homologous recombination [11] . Western blot analysis showed that the ras-containing HCT 116 cells express considerably less Bak than the Hkh-2 cells (Figure 1d) . As with the IEC cells, the ras-induced downregulation of Bak was also observed by northern blot analysis (see Supplementary material). As colorectal tumours have high frequencies of activating K-ras mutations, our observation that activated K-ras is responsible for the reduction of Bak expression in the HCT 116 cells suggests that ras mutations are, at least in part, responsible for the reported downregulation of Bak expression in a large proportion of human colorectal tumours [5] .
To investigate whether the inhibition of Bak expression has a causal role in ras-induced resistance to anoikis in IEC cells, we restored high levels of Bak in the transformed IEC-ras-3 cell line by transfection with a human Bak expression vector. We generated four independent clones (designated Bak43, 45, 55 and 1) that expressed levels of Bak comparable to those observed in the IEC-18 cells, and significantly higher than those of IEC-ras-3 and the clones transfected with vector control (designated Zeo2, 22 and 53). All transfected clones were morphologically similar to the parental IEC-ras-3 cells, with no obvious changes in their growth rate in monolayer culture. The levels of activated ras in these clones remained unchanged ( Figure 2a ).
To investigate the effect of exogenous Bak expression on anoikis, Bak clones and control Zeo clones were cultured as monolayers or in suspension, and apoptosis was assessed using the cell death enzyme-linked immunosorbent assay (ELISA) which measures the release of oligonucleosomes into the cytoplasm. In monolayer culture, none of the Baktransfected clones showed a noticeable increase in cell death compared with IEC-ras-3 clones transfected with vector control (Figure 2b ). In suspension culture, however, the Bak-transfected clones displayed a significant increase in apoptosis (Figure 2b ). Consistent with this result, we found that the ability of the Bak-transfected IEC-ras clones to grow in soft agar was strongly inhibited (~70%; Cells were cultured overnight in monolayer or suspension and the amount of nucleosomal DNA in the cytoplasm was measured by the cell death ELISA. (c) Growth in anchorage-independent conditions. Cells were plated in soft agar, colonies were allowed to form for Figure 2c ). We further confirmed the effect of exogenous Bak on anoikis using an MMTV-ras clone transfected with a Bak expression vector (MMTV-ras-Bak). In the absence of dexamethasone, this clone expressed significantly more Bak than the uninduced control clone transfected with vector alone (MMTV-ras-Zeo). Although both clones maintained similar ability to induce the expression of Hras and downregulate Bak in response to dexamethasone, the levels of Bak in the dexamethasone-treated MMTVras-Bak cells were significantly higher than those of dexamethasone-treated MMTV-ras-Zeo cells (Figure 2d ). As shown for the IEC-ras clones, the ectopic expression of Bak strongly diminished the ras-induced resistance to anoikis in the dexamethasone-treated MMTV-ras-Bak cells (Figure 2e ).
It can be concluded, therefore, that ras-transformed IEC cells can be rendered sensitive to anoikis by restoring higher levels of Bak. It is noteworthy that this reversal of resistance to anoikis in Bak transfectants was significant but not complete, suggesting that activated ras may regulate, in addition to Bak, other effector molecules of the apoptotic machinery involved in anoikis. As transfected Bak did not induce the apoptosis of IEC-ras-3 cells in monolayer culture, it can be concluded that the reduction of Bak levels per se is not sufficient to inactivate the apoptotic machinery in intestinal epithelial cells. Rather, it can be proposed that, in the parental IEC-18 cells, a certain threshold amount of Bak is required for the induction of apoptosis triggered by the absence of survival signals normally generated by integrin-extracellular matrix (ECM) interactions. Hence, when the levels of Bak are reduced, for example as a result of ras activation, the integrininduced death signal becomes ineffective.
As susceptibility to apoptosis is believed to be an important determinant of the malignant phenotype, we compared the tumorigenicity in nude mice of the IEC-ras-3 cells, of a clone transfected with vector control, and of three Bak-transfected clones (Bak45, 55 and 1). Figure 3a shows that the Bak clones were significantly less tumorigenic than the parental IEC-ras cells and the clone transfected with vector control. Because the Bak-transfected clones, especially Bak45 and Bak55, retained some tumorigenicity, we investigated whether cells derived from these tumours acquired a selective growth advantage through the reduction of Bak expression. Tumours derived from clones Bak45 and Bak55 were removed and cell lines re-established. In the case of the Bak45 clone, three out of four tumour-derived cell lines expressed significantly less Bak than the originally injected cell population (Figure 3b ). This trend was even more pronounced in clone Bak55, for which all of the tumour-derived cell lines displayed lower levels of Bak. These data clearly suggest that low Bak expression provides a selective growth advantage for ras-transformed tumour cells in vivo. Therefore, our results clearly demonstrate that molecular changes that affect susceptibility to anoikis without affecting survival in monolayer culture can have a significant impact on tumorigenicity.
In Madin-Darby canine kidney (MDCK) epithelial cells, ras inhibits anoikis through the activation of a PI 3-kinase-protein kinase B (PKB) signaling pathway, but not through a mitogen-activated protein (MAP) kinase pathway [8] . We therefore investigated whether PI 3-kinase is also involved in the ras-induced downregulation of Bak and inhibition of anoikis in IEC cells. IEC-ras-3 cells were treated with the PI 3-kinase inhibitor LY 294002 at a concentration known to efficiently suppress PI 3-kinase (40 µM) [12] . After such treatment, IECras-3 cells displayed a significant increase in the levels of Bak (Figure 4a ( Figure 4c ). PD 98055, on the other hand, did not affect this process (Figure 4c ). Collectively, these results suggest that PI 3-kinase is a mediator of the ras-induced downregulation of Bak expression and resistance to anoikis. In this regard, it is important to note that PKB, an enzyme activated by PI 3-kinase, has recently been shown to suppress apoptosis of neuronal cells by phosphorylating Bad, another pro-apoptotic member of the Bcl-2 family [15] . Phosphorylation of Bad by PKB has also been reported in the case of lymphoid progenitor cells [16] . We are currently investigating whether, in addition to the effect on Bak expression, activated ras can induce Bad phosphorylation in intestinal epithelial cells.
This paper provides support for the notion that the contribution of the ras oncogene to malignant transformation of intestinal epithelial cells is not limited to its effects on cell proliferation. We have already reported that activated ras induces cyclin D1 overexpression, and that this induction is required for the deregulation of cell proliferation [10] . However, the ras-induced deregulation of the cell cycle will have a limited impact on the malignant growth of intestinal epithelial cells, unless these cells acquire the capacity to survive without being attached to the basement membrane, because this is an essential requirement for invasion. It can be concluded, therefore, that the ability of ras to induce Bak downregulation, and the consequent resistance to anoikis, are critical components of the transforming capacity of this oncogene in intestinal epithelial cells.
Supplementary material
Additional figures showing the downregulation of Bak mRNA by activated ras and the upregulation of Bak by LY 294002 upon induction of ras are published with this paper on the internet. The effect of ras activation on the levels of Bak transcripts was assessed by northern blot analysis. In both IEC-18 and HCT 116 cell lines, the presence of activated ras correlated with lower levels of Bak mRNA ( Figure S1 ).
LY 294002 upregulates Bak in dexamethasone-treated MMTV-ras cells
The effect of LY 294002 was also studied in MMTV-ras cells. Treatment with this inhibitor upregulated Bak in the dexamethasone-treated (ras-expressing) cells ( Figure S2c) . A similar treatment of IEC-18 or uninduced MMTV-ras cells, on the other hand, did not alter Bak expression ( Figure S2a,c) . This could be because these cell lines already express high levels of Bak and may have a limited capacity to upregulate the protein further. To confirm that activated ras induces PI 3-kinase activity in IEC cells, and that LY 294002 was acting as an inhibitor of PI 3-kinase, the activity of PKB, a downstream target of PI 3-kinase, was measured in IEC cells expressing constitutive and inducible ras. Figure S2b ,c shows that activated ras strongly induces PKB activity in a PI 3-kinase-dependent manner, because this ras-induced activation was inhibited by LY 294002, whereas the expression of PKB remained essentially unchanged.
